Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Sensorion SA is a biopharmaceutical company dedicated to the development of innovative therapies for inner ear disorders. Known for its cutting-edge research in otoplatform technology, Sensorion aims to address conditions like sudden sensorineural hearing loss, tinnitus, and balance disorders. The company's primary focus is on genomic medicines and small molecules that target and repair cellular paths in the inner ear to restore auditory and vestibular function. Sensorion's work is particularly impactful in the healthcare and pharmaceutical industries, as it seeks to provide solutions to debilitating auditory conditions for which there are currently limited treatment options. Based in France, Sensorion collaborates with academic institutions and industry partners to advance its pipeline of products. As an entity in the biopharmaceutical market, Sensorion's success not only hinges on technological breakthroughs but also regulatory approvals and clinical trial outcomes, which are significant factors in the healthcare sector.
Negative free cash flow of -€28M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
€0.00
Net Income (TTM)
-€29M
▼ -13.3% YoY
Op. Margin
—
ROIC
-40.46%
▲ +0.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€28M
▼ -24.9% YoY
Op. Cash Flow (TTM)
-€28M
▼ -28.2% YoY
Net Debt
-€46M
Net Cash Position
Cash & Equiv.
€47M
Continue Research